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Abstract
A penta-ethyl ester prodrug of the radionuclide decorporation agent diethylenetriaminepentaacetic
acid (DTPA), which exists as an oily liquid, was encapsulated in alginate beads by the ionotropic
gelation method. An optimal formulation was found by varying initial concentrations of DTPA
pentaethyl ester, alginate polymer, Tween 80 surfactant and calcium chloride. All prepared
alginate beads were ~1.6 mm in diameter, and the optimal formulation had loading and
encapsulation efficiencies of 91.0 ± 1.1 and 72.6 ± 2.2%, respectively, and only 3.2 ± 0.8% water
absorption after storage at room temperature in ~80% relative humidity. Moreover, Fourier
transform infrared spectroscopy showed that DTPA penta-ethyl ester did not react with excipients
during formation of the DTPA penta-ethyl ester-containing alginate beads. Release of prodrug
from alginate beads was via anomalous transport, and its stability enhanced by encapsulation.
Collectively, these data suggest that this solid dosage form may be suitable for oral administration
after radionuclide contamination.
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1. Introduction
Diethylenetriaminepentaacetic acid (DTPA) is a chelating agent that can be employed to
enhance decorporation of transuranic elements, e.g., americium (Am), plutonium (Pu) and
curium (Cm), from the human body after internal contamination (Bair & Thompson, 1974).
DTPA is typically administered via intravenous (i.v.) injection, thus requiring well-trained
medical professionals. In the case of a wide-spread contamination emergency, an oral
formulation would be advantageous in that it could be distributed easily and to a large
number of patients. DTPA is hydrophilic and highly ionizable and, therefore, its oral
bioavailability is very low; it is approximately 1% in humans (Cassatt et al., 2008). In order
to improve its oral bioavailability, we esterified the five carboxylic acid functional groups
on DTPA. We previously demonstrated that this prodrug effectively decorporates 241Am
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from contaminated animals (Sueda, Sadgrove, Fitzsimmons, & Jay, 2012). The lipophilic
prodrug, however, is an oily liquid that is prone to hydrolysis and, thus, relatively unstable at
high temperatures and relative humidities (RH). Besides making it more accessible to
patients, dispersing said liquid into a solid matrix could also reduce its interactions with the
environment and, thus, enhance its stability.
The encapsulation of many different oils, including α-tocopherol (Luo, Zhang, Whent, Yu,
& Wang, 2011), wheat germ, lemon and citronella oil (Chana, 2011), have been reported. A
safe and inexpensive strategy for microencapsulation is the preparation of alginate beads.
Alginate, an anionic polysaccharide polymer composed of mannuronic and guluronic acid
residues, extracted from brown algae (Han, Guenier, Salmieri, & Lacroix, 2008), is
extensively used in encapsulation applications, as it is nontoxic, biodegradable and
biocompatible. Alginate forms a gel in the presence of the divalent cation calcium; this
process is termed ionotropic gelation (Cekic et al., 2007;Ramadas, Paul, Dileep, Anitha, &
Sharma, 2000).
The aim of this study was to encapsulate DTPA penta-ethyl ester in alginate beads by the
ionotropic gelation method to enhance prodrug stability. In addition, a solid dosage form of
DTPA penta-ethyl ester would be very desirable in terms of ease of packaging, handling and
administering. An optimal formulation was determined by varying the initial concentrations
of DTPA penta-ethyl ester, alginate, Tween 80 surfactant and calcium chloride (CaCl2). The
optimal formulation of DTPA penta-ethyl ester-containing alginate beads was characterized
and in vitro release and stability of the prodrug investigated.
2. Materials and methods
2.1. Materials
Alginic acid sodium salt (from brown algae; viscosity ≈250 cP; guluronic to manuronic ratio
approximately 39% to 61%), Tween 80, CaCl2 and α-tocopherol were purchased from
Sigma-Aldrich (St Louis, MO, USA), absolute ethanol and acetonitrile were purchased from
Acros Organics (NJ, USA) and DTPA penta-ethyl ester was prepared as previously
described (Sueda et al., 2012).
2.2. Preparation of DTPA penta-ethyl ester-containing alginate beads
Solutions of alginate polymer (1–3%, w/v), Tween 80 surfactant (1–3%, w/v) and CaCl2 (1,
3 and 5%, w/v) were prepared in distilled water. To 1 mL of alginate solution was added
400–800 mg of DTPA penta-ethyl ester and 0.5 mL Tween 80 solution as an emulsifier. The
mixture was homogenized for 2 min at 13,500 rpm at room temperature (RT) and the
emulsion passed through a syringe with a 26-gauge, 3/8 in. needle into a 10 mL CaCl2
solution, under gentle stirring (~700 rpm) at RT for 10 min. The DTPA penta-ethyl ester
alginate beads were then washed three times with distilled water. Encapsulation of DTPA
penta-ethyl ester was frozen at −80 °C for 2 h and was subjected to freeze-drying (FTS
System, Inc. Biopharm Division, NY). Freeze-drying was carried out under conditions with
both primary and secondary drying at a pressure of 100 mTorr. In the first step, primary
drying was carried out at −35 °C for 20 min, −30 °C for 20 min, −25 °C for 20 min, −20 °C
for 20 min, −15 °C for 20 min, −10 °C for 200 min, −5 °C for 30 min, 0 °C for 30 min, 10
°C for 300 min, 20 °C for 300 min; this was followed by secondary drying at 25 °C for 30
min.
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2.3. Characterization of DTPA penta-ethyl ester-containing alginate beads for selection of
an optimal formulation
2.3.1. Drug analysis—The amount of DTPA penta-ethyl ester in various samples was
quantified using a high performance liquid chromatography (HPLC) system (Shimadzu
Prominence UFLC fitted with a Corona charged aerosol detector (CAD) (Dionex/ESA,
USA)). The column was an Alltima™ C18 (250 mm × 2.1 mm; 5 µm) (Grace Davison
Discovery Sciences) and maintained at 40 °C. The flow rate was 0.20 mL/min; the mobile
phase was water with 0.1% trifluoroacetic acid (A), acetonitrile (B) and isopropanol (C).
The mobile phase mixture (A–B–C) followed a linear gradient from 94:4:2 to 10:60:30 over
6.5 min, followed by an isocratic phase of 10:60:30 for 4.5 min (Sueda et al., 2012).
2.3.2. Loading and encapsulation efficiencies—The freeze-dried beads were
weighed (15–20 mg) and then DTPA penta-ethyl ester extracted. The beads were placed in 1
mL of 20 mM ethylenediaminetetraacetic acid (EDTA) in phosphate-buffered saline (PBS),
pH 7.2, and shaken for 10 min at RT. Note that no HPLC peaks associated with the
degradation of DTPA penta-ethyl ester after treatment with EDTA were observed. Nine
milliliters of acetonitrile was subsequently added and the resulting suspension centrifuged at
9000 × g for 15 min at 4 °C to pellet the alginate polymer from the disrupted matrix. One
hundred microliters of this supernatant was added to 900 µL of acetonitrile before analyzing
by the HPLC-CAD method. The pellet was then washed once and the supernatant was
analyzed, but the amount of DTPA penta-ethyl ester found in this fraction was insignificant
(≤0.02 mg). To quantify the amount of DTPA penta-ethyl ester recovered, a standard curve
of DTPA penta-ethyl ester was prepared, and the loading and encapsulation efficiencies
determined using the following formulae:
(1)
where L is the mass of DTPA penta-ethyl ester extracted from DTPA penta-ethyl ester
alginate beads, and L0 is the mass of the DTPA penta-ethyl ester alginate bead, and
(2)
where E is the mass of DTPA penta-ethyl ester extracted and E0 is the theoretical mass of
DTPA penta-ethyl ester.
2.3.3. Particle size analysis and morphology—Particle size was determined using a
micrometer gauge (Sargent, USA) with an accuracy of 0.01 mm. Twenty samples of the
freezedried beads from different formulations were selected and their sizes measured. The
shape and surface morphology of the alginate beads were determined by Scanning Electron
Microscopy (SEM; Super III A model, International Scientific Instruments, Militpas, CA,
USA).
2.3.4. Water absorption—DTPA penta-ethyl ester-containing alginate beads were
weighed before and after storage at RT in a RH of approximately 80% (using a saturated
solution of sodium chloride) until the mass became constant. Water absorption capacity of
the DTPA penta-ethyl ester-containing alginate beads was calculated using the following
equation:
(3)
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where Wa is mass of DTPA penta-ethyl ester-containing alginate beads after storage and Wb
is weight before storage.
2.4. FTIR spectroscopy
FTIR spectra of neat DTPA penta-ethyl ester, DTPA penta-ethyl ester-containing alginate
beads, blank alginate beads and sodium alginate polymer were obtained using a Shimadzu
Prestige-21 FTIR spectrometer. Sixty four scans of each were obtained at a resolution of 4
cm−1 from 4000 to 400 cm−1.
2.5. Dissolution
Dissolution studies were carried out using a USP dissolution Type II apparatus (Hanson
Research Elite 8, Chatsworth, CA) with a paddle rotation speed of 50 rpm in 900 mL
dissolution medium (0.1 N HCl, pH ~1.2) at 37 °C for 45 min. DTPA penta-ethyl ester
alginate beads were weighed accurately (225–230 mg, containing 200 mg DTPA penta-ethyl
ester) and placed in hydroxypropylmethyl cellulose (HPMC) capsules (size: 0), and the
capsules were added to the dissolution medium in the apparatus using sinkers. At specific
time intervals, an aliquot (0.5 mL) was withdrawn using a cannula and passed through a 0.2
µm PVDF filter. The DTPA pentaethyl ester content was then determined by HPLC-CAD.
No residual DTPA penta-ethyl ester was found on the PVDF filter. The dissolution study
was performed in triplicate and the calculated mean values of cumulative release of prodrug
were used for plotting release curves.
2.6. Stability studies
DTPA penta-ethyl ester can undergo oxidation, which results in a change of color. In order
to maintain the stability of DTPA pentaethyl ester, 0.6% of the antioxidant α-tocopherol was
included in neat DTPA penta-ethyl ester and in the optimal formulation of DTPA penta-
ethyl ester-containing alginate beads (formulation D3). After preparation, samples were
placed in HPMC capsules (size: 0) and kept in refrigerated (4 °C), RT (25 °C/80% RH) or
accelerated (40 °C/80% RH) storage for three months. The remaining intact DTPA penta-
ethyl ester was determined using the HPLC-CAD method.
2.7. Statistical analysis
Data are presented as the mean ± standard deviation (STD). Each experiment was repeated
at least three times and an unpaired t test was used to establish the significance of
differences among groups. Differences were considered statistically significant if p < 0.05
(*).
3. Results and discussion
3.1. Appearance and morphology of DTPA penta-ethyl ester-containing alginate beads
A photograph of blank and DTPA penta-ethyl ester-containing alginate beads after freeze
drying are shown in Fig. 1A. The DTPA penta-ethyl ester-containing alginate beads are
yellow, due to the encapsulation of DTPA penta-ethyl ester, which is a yellow oily liquid
(Fig. 1A, left). The alginate beads were spherical and smooth, but after freeze-drying, both
blank and DTPA penta-ethyl ester-containing alginate beads had irregular shapes and
surfaces that were not smooth. In the SEM image of a DTPA penta-ethyl ester-containing
alginate bead after freeze drying (Fig. 1B), the irregular surface can be easily seen. Mean
particle sizes of the DTPA pentaethyl ester containing alginate beads are shown in Table 1
and were in the range of 1.58–1.63 mm. No significant differences in particle size were
observed among the various formulations.
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3.2. Characterization of DTPA penta-ethyl ester-containing alginate beads for selection of
an optimal formulation
Various components of the alginate bead formulation were varied to determine an optimal
solid dosage form for subsequent studies. It was previously demonstrated that a single 40
mg/kg oral dose of DTPA penta-ethyl ester improved decorporation of 241Am from
contaminated rats, compared to a no-treatment control group (Sueda et al., 2012). High
loading and encapsulation efficiencies were sought to accommodate a large dose of the
prodrug. Low water absorption is favored because ester functional groups on the DTPA
prodrug can be hydrolyzed (Waterman et al., 2002). Therefore, the percent water absorption
in the formulations was also determined.
Increasing the concentration of CaCl2 from 1% to 5% (w/v) at fixed alginate, Tween 80 and
prodrug concentrations resulted in decreased loading and encapsulation efficiencies and
increased water absorption (Table 1; A1–3). This is consistent with previous reports that
showed that increasing calcium concentration in the formulation can decrease encapsulation
of the active compound in alginate beads (Østberg & Graffner, 1994;Pongjanyakul &
Rongthong, 2010). Furthermore, it is known that CaCl2 readily absorbs moisture from the
air.
Increasing the concentration of alginate from 1% to 3% (w/v) at fixed CaCl2, Tween 80 and
prodrug concentrations resulted in no change in the loading efficiency, but higher
encapsulation efficiencies and increased water absorption (Table 1; B1–3). Others have
shown that encapsulation of a compound in alginate beads increases with increasing
concentrations of alginate (El-Kamel, Al-Gohary, & Hosny, 2003;Manjanna, Pramod
Kumar, & Shivakumar, 2010). The increased water absorption was probably due to the
hydrophilic nature of the alginate polymer.
Tween 80 was used here to emulsify the lipophilic DTPA pentaethyl ester and the alginate
solution. Table 1(C1–3) shows the effects of varying the concentration of Tween 80 on
loading and encapsulation efficiencies and water absorption. The higher loading and
encapsulation efficiencies were observed when using 2% Tween 80; no differences in water
absorption were observed. The effects of varying the prodrug concentration on loading and
encapsulation efficiencies and water absorption are shown in the Table 1(D1–3). Using
higher concentrations of the prodrug resulted in greater loading and encapsulation
efficiencies. This is consistent with earlier reports (Hari, Chandy, & Sharma, 1996;Wan,
Heng, & Chan, 1992) in that increasing the concentration of the active compound in the
alginate aqueous phase of the emulsion yielded increased encapsulation. Furthermore, an
increase in the concentration of drug in the formulation resulted in a decrease in water
absorption.
The D3 formulation was chosen as the optimal formulation and was used in subsequent
experiments. Its loading and encapsulation efficiencies were the highest achieved, at 91.0 ±
1.1 and 72.6 ± 2.2%, respectively. Its water absorption was the second lowest at 3.2 ± 0.8%.
3.3. FTIR spectroscopy
Interactions between drug and carrier can lead to identifiable changes in the FTIR spectrum
of a solid dosage form. Thus, FTIR spectra of DTPA penta-ethyl ester, sodium alginate
polymer, and blank and DTPA penta-ethyl ester-containing alginate beads were obtained
(Fig. 2). The spectrum of DTPA penta-ethyl ester has absorptions at 2983, 1732, 1190 and
1029 cm−1, which correspond to sp3 CH2 and CH3, C=O, C–O and C–N stretching
vibrations, respectively. In the sodium alginate spectrum, the absorptions at 3394 cm−1 and
1637 cm−1 correspond to the stretching vibrations of OH and C=O, respectively. When
alginate beads are formed, the aforementioned C=O stretching vibration shifts to a higher
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wavenumber (1738 cm−1) (Sartori, Finch, & Ralph, 1997). In the FTIR spectrum of the
DTPA penta-ethyl ester-containing alginate beads, absorptions associated with DTPA penta-
ethyl ester are observed that do not differ in position from neat prodrug. Thus, DTPA penta-
ethyl ester did not appear to react with excipients during formation of DTPA penta-ethyl
ester-containing alginate beads.
3.4. Dissolution
The in vitro release profile of DTPA penta-ethyl ester in dissolution medium (0.1 N HCl, pH
1.2) at 37 °C from DTPA penta-ethyl ester-containing alginate beads in HPMC capsules
(size 0) is shown in Fig. 3. It was previously demonstrated that DTPA penta-ethyl ester
exhibits pH-dependent solubility and lipophilicity favorable for oral absorption, and that it is
sufficiently stable at low pH to avoid extensive degradation in the gastrointestinal tract prior
to absorption (Sueda et al., 2012). At pH 1.2, the HMPC capsules dissolved rapidly (~4
min). After 20 min, 97 ± 2% of the prodrug was solubilized in the dissolution medium.
When neat DTPA pentaethyl ester was placed in the same type of HPMC capsule and
dissolution medium at 37 °C, 80 ± 10% was solubilized after 20 min (data not shown). The
dispersal of the prodrug in the matrix probably decreased hydrophobic interactions among
the DTPA penta-ethyl ester molecules, in that drug was spread over a larger surface area,
increasing the dissolution rate.
The following semi-empirical equation (Ritger & Peppas, 1987;Siepmann & Peppas, 2001)
can be used to describe the release mechanism from swellable polymeric systems:
(4)
In logarithmic form it is:
(5)
where Mt/M∞ represents the fraction release of the drug at time t, k is the release rate
constant and n is the release exponent indicative of the drug release mechanism. For spheres
(Table 2), values of n between 0.43 and 0.85 are an indication of anomalous transport.
Values for n higher than 0.85 indicate case-II transport, which relates to polymer relaxation
during hydrogel swelling, and values lower than 0.43 indicate that drug release is because of
Fickian diffusion (Siepmann & Peppas, 2001;Takka, Ocak, & Acarturk, 1998). The values
of the aforementioned terms in this system are listed in Table 2. The n value is 0.529,
indicating that the release of DTPA penta-ethyl ester from the alginate beads is via
anomalous transport. The anomalous transport is mainly controlled by the swelling of the
alginate beads; free water penetrates the alginate beads via its pores and swells the matrix.
Prodrug diffuses out through the beads with simultaneous polymer relaxation. The
experimental data satisfy linear fitting up to 86% DTPA penta-ethyl ester release, near the
onset of the plateau, with a correlation coefficient (r2) of 0.997.
3.5. Stability and in vitro release in the presence of 0.6% α-tocopherol
Because DTPA penta-ethyl ester is susceptible to oxidation and the hydrolysis of its ester
functional groups, encapsulation of DTPA penta-ethyl ester is expected to enhance its
stability by reducing its interactions with the environment. Neat DTPA penta-ethyl ester was
placed in HPMC capsules with 0.6% α-tocopherol and stored at 4 °C, 25 °C and 40 °C, all
at approximately 80% RH. After three months, 77 ± 2, 68 ± 1 and 0.6 ± 0.9% of DTPA
penta-ethyl ester remained intact, respectively (Fig. 4A). DTPA penta-ethyl estercontaining
Yang et al. Page 6













alginate beads (formulation D3) with 0.6% α-tocopherol were placed in HPMC capsules and
stored at the same temperatures and RH. After three months, 88 ± 3, 79 ± 3 and 51 ± 2% of
DTPA penta-ethyl ester remained intact, respectively (Fig. 4A). Thus, improved stability of
the prodrug was observed after encapsulation in alginate beads.
4. Conclusions
The present study demonstrated that DTPA penta-ethyl ester, which exists as an oily liquid,
can be made into a solid dosage form using alginate polymer and CaCl2 by ionotropic
gelation. High content DTPA penta-ethyl ester-containing alginate beads were produced.
The prodrug did not react with excipients during formation of DTPA penta-ethyl ester-
containing alginate beads and increased stability of the prodrug was observed when
encapsulated in the beads. Future efforts are being devoted to preparing a polymer-coated
alginate bead to further protect the active ingredient from hydrolytic and oxidative
degradation.
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Photograph of DTPA penta-ethyl ester-containing alginate beads (left) and blank alginate
beads (right) (A); SEM image of a DTPA penta-ethyl ester alginate bead (B).
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FTIR spectra of sodium alginate polymer, blank and DTPA penta-ethyl ester-containing
alginate beads and neat DTPA penta-ethyl ester.
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Percent of the DTPA penta-ethyl ester released and solubilized in dissolution medium (0.1 N
HCl, pH 1.2) from alginate beads in HPMC capsules. Values are mean ± standard deviation,
n = 3.
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Stability of neat DTPA penta-ethyl ester with 0.6% α-tocopherol or DTPA penta-ethyl ester-
containing alginate beads with 0.6% α-tocopherol in HPMC capsules after storage at 4 °C,
25 °C and 40 °C (all ~80% RH) for three months. Values are mean ± standard deviation, n =
3.
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Table 2
Release mechanisms from polymeric delivery systems of different geometry and drug release mechanism of
DTPA penta-ethyl ester from alginate beads.
Exponent, n Drug release mechanism
Thin film Cylinder Sphere
0.5 0.45 0.43 Fickian diffusion
0.5 < n < 1.0 0.45 < n < 0.89 0.43 < n < 0.85 Anomalous transport
1 0.89 0.85 Case-II transport
Drug release mechanism of DTPA penta-ethyl ester from alginate beadsa
n k (×102) r2
0.529 28.89 0.997 Anomalous transport
a
Diffusional exponent (n), kinetic constant (k) and correlation coefficient (r) by linear regression of log (Mt/M∞) versus log t; k is the constant
related to the structural and geometric characteristics of the device; n is the diffusional exponent, which is indicative of release mechanism.
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